AstraZeneca secures FDA approval for Imfinzi combo in MIBC
The US Food and Drug Administration (FDA) has approved AstraZeneca's Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult…
The US Food and Drug Administration (FDA) has approved AstraZeneca's Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult…
The US Food and Drug Administration (FDA) has declined to approve Summit Therapeutics’ biologics licence application (BLA) for ivonescimab in…
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective…
Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy…
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to…
Life sciences consulting firms Litmys and PharmaACE have formed a strategic collaboration to provide commercial forecasting and decision-making services to…
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an…
Oyster Therapeutics, formerly known as Kesmalea Therapeutics, has closed a $60m Series A-2 financing round to advance targeted protein degraders…
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an…
Charles River Laboratories International (CRL) has signed definitive agreements to acquire Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK)…